대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	추계학술대회 초록집
제목	Update on Treatment of Lupus Nephritis
저자	Jang-Hee Cho
출판정보	2014; 2014(2):
키워드
초록	Systemic lupus erythematosus (SLE) presents clinical evidence of lupus nephritis in approximately 35% of patients at the diagnosis, with total of 50~60% developing nephritis during 10 years of disease. The presence of lupus nephritis significantly deteriorated the patient survival to 88% at 10 years, which is much lower survival compared with the survival of patients without lupus nephritis. The recent published guidelines suggested two phases of therapy for lupus nephritis class III/IV as induction and maintenance phases. Cyclophsophamide (CYC) or mycophenolate mofetil (MMF) combined with steroid pulse followed by high-dose steroid is recommended as the first line agents for induction therapy. To the improved patients after induction, MMF or azathioprine with low-dose steroid is used as maintenance therapy. Although MMF and CYC are equally effective in short-term induction, it is needed to investigate whether MMF are also effective as CYC in longterm outcomes. Various novel biologic agents and small molecules have been studied to treat lupus nephritis. However, many trials in general have not succeeded in improve short-term end points. Short-term kidney response might be improved better with anti-inflammatory therapy than anti-autoimmune therapy to which most novel agent was categorized. The optimal approach for using novel therapeutics might be an introduction of new treatment paradigm of lupus nephritis; after initiation of anti-inflammatory therapy, novel therapy should be administered for targeting autoimmune mechanisms
원문(PDF)	PDF 원문보기

목록

위로가기